The bisphosphonate incadronate for bone metastases of breast cancer

被引：5
作者：
Koizumi M. [1 ]
Kobayashi M. [2 ]
Furukawa M. [2 ]
Yamashita T. [2 ]
Ogata E. [3 ]
机构：
[1] Department of Nuclear Medicine, Cancer Institute Hospital, 1-37-1 Kami-Ikebukuro, Toshima-ku
[2] Department of Radiotherapy, Cancer Institute Hospital, Tokyo
[3] Department of Internal Medicine, Cancer Institute Hospital, Tokyo
来源：
International Journal of Clinical Oncology | 2000年 / 5卷 / 4期
关键词：
Bisphosphonate; Bone Metabolic markers; Bone metastasis; Breast cancer; Tumor marker;
D O I：
10.1007/PL00012044
中图分类号：
学科分类号：
摘要：
Background. Bisphosphonates are bone resorption inhibitors which are effective in the treatment of diseases of increased bone turnover, such as hypercalcemia of malignancy and osteolytic bone metastasis. The safety and efficacy of incadronate, a third-generation bisphosphonate, were evaluated in breast cancer patients with bone metastases. Methods. Fifteen breast cancer patients with bone metastasis were enrolled. Incadronate's safety, its effectiveness in relieving bone pain, and its effects on bone metabolic markers and a tumor marker were assessed in 8 patients treated with a 10-mg IV infusion once a week for 5 weeks (10mg x 5), 3 patients treated with a single 20-mg IV infusion (20mg x 1), and 4 patients treated with a 20-mg IV infusion once a week for 5 weeks (20mg x 5). Pain assessment was performed only in the patients with the repeated infusion regimens. Results. All incadronate treatment regimens were administered without any serious adverse reactions. Minimal fever was noted in 6 patients, but it subsided without any treatment. Incadronate relieved bone pain in 10 of the 12 patients who received repeated infusions. Levels of bone resorption markers dropped transiently, but the decreases in the individual markers of bone resorption varied. Levels of bone formation markers did not change significantly. Levels of a tumor marker specific to breast cancer, carbohydrate antigen (CA)15-3 decreased in patients whose metastases were limited to bone. Conclusion. The third-generation bisphosphonate, incadronate, was administered safely at dosages of up to 20mg once a week for 5 weeks. Incadronate reduced bone pain, bone resorption marker levels, and CA15-3 tumor marker levels in breast cancer patients with bone metastases.
引用
收藏
页码：241 / 246
页数：5
相关论文
共 16 条
  • [1] Hiraga T., Tanaka S., Ikegami M., Et al., Morphology of bone metastasis, Eur J Cancer, 34, pp. 230-239, (1998)
  • [2] Jung A., Bizas S., Fleisch H., The binding of pyrophosphate and two diphosphonates on hydroxyapatite, Calcif Tissue Res, 11, pp. 269-280, (1973)
  • [3] Flanagan A.M., Chambers T.J., Inhibition of bone resorption by bisphosphonates: Interactions between bisphosphonates, osteoclasts, and bone, Calcif Tissue Int, 49, pp. 407-415, (1991)
  • [4] Fukumoto S., Matsumoto T., Takabe K., Et al., Treatment of malignant associated hypercalcemia with YM175, a new bisphosphonate: Elevated threshold for parathyroid hormone secretion in hypercalcemic patients, J Clin Endocrinol Metab, 79, pp. 165-170, (1994)
  • [5] Hortobagyi G.N., Theriault R., Porter L., Et al., Efficacy of pamidronate in reducing Skeletal complications in patients with breast cancer and lytic bone metastases, N Engl J Med, 335, pp. 1785-1791, (1996)
  • [6] Diel I.J., Solomayer E.F., Costa S.D., Et al., Reduction in new metastases in breast cancer with adjuvant clodronate treatment, N Engl J Med, 339, pp. 357-363, (1998)
  • [7] Kanis J.A., Powles T., Paterson A.H.G., Et al., Clodronate decreases the frequency of skeletal metastases in women with breast cancer, Bone, 19, pp. 663-667, (1996)
  • [8] Pluijm G., Vloedgraven H., Beek E., Et al., Bisphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro, J Clin Invest, 98, pp. 698-705, (1996)
  • [9] Shipman C.M., Croucher P.I., Russell G.G., Et al., The bisphosphonate incadronate (YM-175) causes apoptosis of human myeloma cells in vitro by inhibiting the mevalonate pathway, Cancer Res, 58, pp. 5294-5297, (1998)
  • [10] Koizumi M., Sekine H., Aoki M., Et al., Efficacy of YM-175, a new bisphosphonate, in the treatment of metastatic bone tumor from breast cancer and its effect on scintigraphy, Int J Clin Oncol, 1, pp. 18-22, (1996)
12